利福霉素钠与利福平治疗肺结核安全性评价

目的 比较利福霉素钠和利福平在治疗肺结核中的安全性.方法 792例肺结核患者分为利福霉素钠组(393例)和利福平组(399例),治疗2个月后评价其安全性.结果 利福霉素钠不良反应发生率(12.47％),较利福平(18.29％)低,严重不良反应发生率:利福霉素钠为1.78％,利福平为5.76％,差异有统计学意义;主要表现为肝损伤、过敏反应、肾功能损伤、血细胞减少和消化道不适.结论 利福霉素钠的不良反应发生率和严重程度小于利福平,若患者不能耐受利福平,可考虑利福霉素钠作为替代治疗.

The safety evaluation of rifamycin sodium and rifampicin in the treatment of tuberculosis

Objective To compare the safety of rifamycin sodium with rifampicin for the treatment of tuberculosis (TB).Methods 792 TB patients were divided into the rifamycin sodium group (n=393) and the RIF group (n=399). The safety was evaluated after treatment for 2 months.Results The incidence of adverse reactions in the rifamycin sodium group (12.47%) was lower than the RIF group (18.29%) The incidence of serious ADR in the rifamycin sodium group was 1.78%, while the RIF group was 5.76%. The difference was statistically significant. The ADR included liver injury, anaphylactic reaction, renal injury, hypocytosis and di-gestive discomfort.Conclusion The incidence and severity of adverse reactions of rifamycin sodium is lower than rifampicin. Rifamycin sodium can be considered as a choice if rifampicin is not tolerated.